SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
21466366
Source:
http://linkedlifedata.com/resource/pubmed/id/21466366
Search
Subject
(
55
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0001758
,
umls-concept:C0019829
,
umls-concept:C0021760
,
umls-concept:C0229671
,
umls-concept:C0439658
,
umls-concept:C0439858
,
umls-concept:C0441889
pubmed:issue
4
pubmed:dateCreated
2011-4-6
pubmed:abstractText
Interleukins (ILs) 6, 10, and 13 seem to be important in the pathogenesis of Hodgkin lymphoma (HL), but there is insufficient data on the serum levels of these cytokines in patients with HL.
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/7607091
pubmed:citationSubset
AIM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents
,
http://linkedlifedata.com/resource/pubmed/chemical/IL10 protein, human
,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-10
,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-13
,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6
,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukins
,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1543-2165
pubmed:author
pubmed-author:DominguesMaria A CMA
,
pubmed-author:GaiollaRafael DRD
,
pubmed-author:Niéro-MeloLígiaL
,
pubmed-author:de OliveiraDeilson ElguiDE
pubmed:issnType
Electronic
pubmed:volume
135
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
483-9
pubmed:meshHeading
pubmed-meshheading:21466366-Adult
,
pubmed-meshheading:21466366-Antineoplastic Agents
,
pubmed-meshheading:21466366-Disease Progression
,
pubmed-meshheading:21466366-Drug Monitoring
,
pubmed-meshheading:21466366-Female
,
pubmed-meshheading:21466366-Hodgkin Disease
,
pubmed-meshheading:21466366-Humans
,
pubmed-meshheading:21466366-Interleukin-10
,
pubmed-meshheading:21466366-Interleukin-13
,
pubmed-meshheading:21466366-Interleukin-6
,
pubmed-meshheading:21466366-Interleukins
,
pubmed-meshheading:21466366-Male
,
pubmed-meshheading:21466366-Neoplasm Staging
,
pubmed-meshheading:21466366-Time Factors
,
pubmed-meshheading:21466366-Treatment Outcome
,
pubmed-meshheading:21466366-Tumor Markers, Biological
,
pubmed-meshheading:21466366-Young Adult
pubmed:year
2011
pubmed:articleTitle
Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma.
pubmed:affiliation
Department of Internal Medicine, Botucatu Medical School, São Paulo State University, Botucatu, Brazil. rgaiolla@fmb.unesp.br
pubmed:publicationType
Journal Article
,
Research Support, Non-U.S. Gov't